Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting.

Bhushan R, Elkind-Hirsch KE, Bhushan M, Butler WJ, Duncan K, Marrioneaux O

Diabetes technology & therapeutics1 Jun 2009Cited by 21 (Europe PMC)

PMID19459763DOI10.1089/dia.2008.0090PepBankPUB-19459763

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanObservational studyEfficacy outcome
In patients with type 2 diabetes and metabolic syndrome, adjunctive exenatide was linked to lower HbA1c than baseline.
In plain wordsIn patients with diabetes and metabolic syndrome, exenatide was linked to lower HbA1c than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c
Study
n = 176
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 16 (+/-4) weeksAs given in this study (human).
Source sentences
Summary
Mean HbA(1c) was significantly reduced from baseline in 16 weeks (P < 0.001), with 68% of patients achieving HbA(1c) <7%.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective analysis of clinical data extracted from the records of 176 adult patients with T2DM and MetS (106 women, 70 men) who received exenatide along with existing therapeutic regimes from 2005 to 2007 was performed.
Summary · context
HbA(1c), lipid profiles, blood pressure, and anthropometric measures were evaluated at baseline and after 16 (+/-4) weeks of exenatide therapy.
Report a problemFND-1945976301
02HumanObservational studyEfficacy outcome
In patients with type 2 diabetes and metabolic syndrome, 68% achieved HbA1c below 7% during exenatide treatment.
In plain wordsIn patients with diabetes and metabolic syndrome, 68% reached HbA1c below 7% during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableHbA1c below 7%
Study
n = 176
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 16 (+/-4) weeksAs given in this study (human).
Measurements
Responders
68%
HbA1c below 7%
Source sentences
Summary
Mean HbA(1c) was significantly reduced from baseline in 16 weeks (P < 0.001), with 68% of patients achieving HbA(1c) <7%.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective analysis of clinical data extracted from the records of 176 adult patients with T2DM and MetS (106 women, 70 men) who received exenatide along with existing therapeutic regimes from 2005 to 2007 was performed.
Summary · context
HbA(1c), lipid profiles, blood pressure, and anthropometric measures were evaluated at baseline and after 16 (+/-4) weeks of exenatide therapy.
Report a problemFND-1945976302
03HumanObservational studyEfficacy outcome
In patients with diabetes and metabolic syndrome, exenatide was linked to lower total cholesterol than baseline.
In plain wordsIn patients with diabetes and metabolic syndrome, exenatide was linked to lower total cholesterol than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTotal cholesterol
Study
n = 176
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 16 (+/-4) weeksAs given in this study (human).
Source sentences
Summary
Total, high-density lipoprotein-, and low-density lipoprotein-cholesterol levels decreased significantly.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective analysis of clinical data extracted from the records of 176 adult patients with T2DM and MetS (106 women, 70 men) who received exenatide along with existing therapeutic regimes from 2005 to 2007 was performed.
Summary · context
HbA(1c), lipid profiles, blood pressure, and anthropometric measures were evaluated at baseline and after 16 (+/-4) weeks of exenatide therapy.
Report a problemFND-1945976303
04HumanObservational studyEfficacy outcome
In patients with diabetes and metabolic syndrome, exenatide was linked to lower HDL cholesterol than baseline.
In plain wordsIn patients with diabetes and metabolic syndrome, exenatide was linked to lower HDL cholesterol than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHDL cholesterol
Study
n = 176
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 16 (+/-4) weeksAs given in this study (human).
Source sentences
Summary
Total, high-density lipoprotein-, and low-density lipoprotein-cholesterol levels decreased significantly.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective analysis of clinical data extracted from the records of 176 adult patients with T2DM and MetS (106 women, 70 men) who received exenatide along with existing therapeutic regimes from 2005 to 2007 was performed.
Summary · context
HbA(1c), lipid profiles, blood pressure, and anthropometric measures were evaluated at baseline and after 16 (+/-4) weeks of exenatide therapy.
Report a problemFND-1945976304
05HumanObservational studyEfficacy outcome
In patients with diabetes and metabolic syndrome, exenatide was linked to lower LDL cholesterol than baseline.
In plain wordsIn patients with diabetes and metabolic syndrome, exenatide was linked to lower LDL cholesterol than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseLDL cholesterol
Study
n = 176
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 16 (+/-4) weeksAs given in this study (human).
Source sentences
Summary
Total, high-density lipoprotein-, and low-density lipoprotein-cholesterol levels decreased significantly.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective analysis of clinical data extracted from the records of 176 adult patients with T2DM and MetS (106 women, 70 men) who received exenatide along with existing therapeutic regimes from 2005 to 2007 was performed.
Summary · context
HbA(1c), lipid profiles, blood pressure, and anthropometric measures were evaluated at baseline and after 16 (+/-4) weeks of exenatide therapy.
Report a problemFND-1945976305
06HumanObservational studyEfficacy outcome
In patients with diabetes and metabolic syndrome, exenatide was linked to lower body mass index than baseline.
In plain wordsIn patients with diabetes and metabolic syndrome, exenatide was linked to lower body mass index than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody mass index
Study
n = 176
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 16 (+/-4) weeksAs given in this study (human).
Source sentences
Summary
Significant reductions were also noted in body mass index, mean body weight, and abdominal girth (AG) with the addition of exenatide.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective analysis of clinical data extracted from the records of 176 adult patients with T2DM and MetS (106 women, 70 men) who received exenatide along with existing therapeutic regimes from 2005 to 2007 was performed.
Summary · context
HbA(1c), lipid profiles, blood pressure, and anthropometric measures were evaluated at baseline and after 16 (+/-4) weeks of exenatide therapy.
Report a problemFND-1945976306
07HumanObservational studyEfficacy outcome
In patients with diabetes and metabolic syndrome, exenatide was linked to lower body weight than baseline.
In plain wordsIn patients with diabetes and metabolic syndrome, exenatide was linked to lower body weight than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 176
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 16 (+/-4) weeksAs given in this study (human).
Source sentences
Summary
Significant reductions were also noted in body mass index, mean body weight, and abdominal girth (AG) with the addition of exenatide.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective analysis of clinical data extracted from the records of 176 adult patients with T2DM and MetS (106 women, 70 men) who received exenatide along with existing therapeutic regimes from 2005 to 2007 was performed.
Summary · context
HbA(1c), lipid profiles, blood pressure, and anthropometric measures were evaluated at baseline and after 16 (+/-4) weeks of exenatide therapy.
Report a problemFND-1945976307
08HumanObservational studyEfficacy outcome
In patients with diabetes and metabolic syndrome, exenatide was linked to lower abdominal girth than baseline.
In plain wordsIn patients with diabetes and metabolic syndrome, exenatide was linked to lower abdominal girth than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAbdominal girth
Study
n = 176
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 16 (+/-4) weeksAs given in this study (human).
Source sentences
Summary
Significant reductions were also noted in body mass index, mean body weight, and abdominal girth (AG) with the addition of exenatide.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective analysis of clinical data extracted from the records of 176 adult patients with T2DM and MetS (106 women, 70 men) who received exenatide along with existing therapeutic regimes from 2005 to 2007 was performed.
Summary · context
HbA(1c), lipid profiles, blood pressure, and anthropometric measures were evaluated at baseline and after 16 (+/-4) weeks of exenatide therapy.
Report a problemFND-1945976308
09HumanObservational studyEfficacy outcome
In patients with diabetes and metabolic syndrome, 76% lost weight during exenatide treatment.
In plain wordsIn patients with diabetes and metabolic syndrome, 76% lost weight during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableWeight loss responders
Study
n = 176
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 16 (+/-4) weeksAs given in this study (human).
Measurements
Weight loss responders
76%
exenatide
Source sentences
Summary
Additional analyses showed 76% of subjects lost weight.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective analysis of clinical data extracted from the records of 176 adult patients with T2DM and MetS (106 women, 70 men) who received exenatide along with existing therapeutic regimes from 2005 to 2007 was performed.
Summary · context
HbA(1c), lipid profiles, blood pressure, and anthropometric measures were evaluated at baseline and after 16 (+/-4) weeks of exenatide therapy.
Report a problemFND-1945976309
10HumanObservational studyEfficacy outcome
In exenatide-treated patients with diabetes, abdominal girth reduction was more pronounced in women than men.
In plain wordsIn exenatide-treated patients with diabetes, women had greater waist reduction than men.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSex difference in abdominal girth reduction
Study
n = 176
Comparator
Male patients
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 16 (+/-4) weeksAs given in this study (human).
Source sentences
Summary
Lessening of AG was much more pronounced in female compared with male subjects with diabetes (P < 0.032).
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective analysis of clinical data extracted from the records of 176 adult patients with T2DM and MetS (106 women, 70 men) who received exenatide along with existing therapeutic regimes from 2005 to 2007 was performed.
Summary · context
HbA(1c), lipid profiles, blood pressure, and anthropometric measures were evaluated at baseline and after 16 (+/-4) weeks of exenatide therapy.
Report a problemFND-1945976310
11HumanObservational studyEfficacy outcome
In patients with diabetes and metabolic syndrome, no consistent blood pressure changes occurred during exenatide treatment.
In plain wordsIn patients with diabetes and metabolic syndrome, blood pressure showed no consistent change from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedBlood pressure
Study
n = 176
Comparator
Baseline
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 16 (+/-4) weeksAs given in this study (human).
Source sentences
Summary
No consistent changes in blood pressure were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective analysis of clinical data extracted from the records of 176 adult patients with T2DM and MetS (106 women, 70 men) who received exenatide along with existing therapeutic regimes from 2005 to 2007 was performed.
Summary · context
HbA(1c), lipid profiles, blood pressure, and anthropometric measures were evaluated at baseline and after 16 (+/-4) weeks of exenatide therapy.
Report a problemFND-1945976311

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.